AIDSInfo logo
Home > Clinical Guidelines > Adult and Adolescent Guidelines

Adult and Adolescent Guidelines

Related Content
Order PublicationSupplementsSlide SetsManualsFact Sheets
DrugsHow to CiteClinical Trials 
DrugsBack
Adapted from Adult Treatment Guidelines Table 6: Antiretroviral Therapy for Treatment-Naive Patients (Updated November 3, 2008)

Patients naive to antiretroviral therapy should be started on a combination regimen that consists of either: 1 NNRTI + 2 NRTIs or 1 PI (preferably boosted with ritonavir) + 2 NRTIs 
  NNRTI Options Population in which to avoid or use with caution
Preferred  
  Efavirenz Do not use during 1st trimester of pregnancy or in those with high pregnancy potential  
      Use with caution in patients with unstable psychiatric disease  
         
  Alternative      
  Nevirapine   Do not use in patients with moderate to severe hepatic impairment (Child-Pugh score B or C)   
      Do not use in women with pre-ARV CD4 >250 or in men with pre-ARV CD4 >400  
      Use with caution in patients on tenofovir/emtricitabine (or lamivudine). Early virologic failure has been reported with this combination.   
PI Options Population in which to avoid or use with caution
  Preferred (alphabetical order)      
  Atazanavir + ritonavir (1x/day)   Do not use in patients who require high-dose (>20mg omeprazole equivalent/day) proton pump inhibitors (PPIs)  
  Darunavir +ritonavir (1x/day)      
  Fosamprenavir + ritonavir (2x/day)      
  Lopinavir/ritonavir (1x or 2x/day)   Do not use lopinavir/ritonavir in pregnant women   
  Alternative (alphabetical order)      
  Atazanavir (unboosted)(1x/day)   Do not use atazanavir in combination with tenofovir or didanosine/lamivudine  
  Fosamprenavir + ritonavir (1x/day) or fosamprenavir unboosted (2x/day)      
  Saquinavir + ritonavir (2x/day)      
         
  Dual-NRTI Options Population in which to avoid or use with caution
  Preferred      
  Emtricitabine/tenofovir   Do not use in combination with unboosted atazanavir  
      Use with caution:  
with nevirapine due to reports of early virologic failure
      in patients with underlying renal insufficiency  
  Alternative      
  Abacavir/lamivudine   Do not use in patients who test positive for HLAB*5701  
      Use with caution in the presence of the following:  
      HIV RNA >100,000 copies/mL - higher rate of virologic failure reported in ACTG 5205  
      High risk for cardiovascular disease  
  Didanosine + lamivudine (or emtricitabine)   Do not use in combination with unboosted atazanavir  
      Do not use in patients with a history of pancreatitis or peripheral neuropathy  
  Zidovudine/lamivudine   Do not use in combination with unboosted atazanavir  
      Do not use in patients with a history of pancreatitis or peripheral neuropathy  
      Use with caution in the presence of pretreatment anemia and/or neutropenia (may improve or worsen with zidovudine)  
         
         
CitationBack
How to Cite the Adult and Adolescent Guidelines:
Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; pp 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed (insert date) [insert page number, table number, etc. if applicable]
Clinical TrialsBack
17 studies were listed in the last 30 days.            

RecruitingTesting an HIV Prevention Intervention for Psychiatric Patients in Brazil
Condition: HIV Infection
RecruitingProspective Longitudinal Pilot Study on the Effect of Intensification With Raltegravir +/- PI or NNRTI on HIV in the GALT
Condition: HIV Infections
Not yet recruitingHigh-Dose Fluconazole for the Treatment of CM in HIV-Infected People
Condition: Cryptococcal Meningitis; HIV Infections
RecruitingHepatitis B Vaccination (HBV) in HIV Infected Children
Condition: HIV Infection
RecruitingMaraviroc in Immunological Non-Responder (INR) HIV-1-Infected Subjects
Condition: HIV Infections
RecruitingDisulfiram Interactions With HIV Medications: Clinical Implications
Condition: HIV Infections; Drug Abuse
Not yet recruitingInteractions Between Artemether-Lumefantrine and Antiretrovirals in HIV-Patients With Uncomplicated Malaria in Tanzania
Condition: Uncomplicated Malaria; HIV Infections
Not yet recruitingStudy for HIV Prevention in Young Hispanic Men
Condition: HIV Infections
Not yet recruitingAtazanavir and Lamivudine for Treatment Simplification
Condition: HIV Infections
Recruiting7-Valent Pneumococcal Conjugated Vaccination
Condition: Invasive Pneumococcal Disease
RecruitingStudy of DDT and Loss of Clinically-Recognized Pregnancies in South Africa
Condition: Spontaneous Abortion; Malaria; Pregnancy Outcome; Stillbirth; HIV
Not yet recruitingTreatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
Condition: Anxiety Disorders
RecruitingInteraction of Buprenorphine With HIV Medications and Tuberculosis Medications
Condition: Opioid Dependency
Not yet recruitingEmpowerment Intervention for Young Women - Phase I
Condition: HIV; Empowerment
RecruitingSafety and Efficacy of GS-9350-Boosted Atazanavir Compared to Ritonavir-Boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Not yet recruitingSunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
Condition: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous/Nonmalignant Condition; Unspecified Adult Solid Tumor, Protocol Specific
Not yet recruitingChanges in Lipids and Safety of Raltegravir Based Antiretroviral Therapy in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
Condition: HIV; Hyperlipidemia; Hypertriglyceridemia
 
Important Notice:
This document has been submitted for publication to CDC's Morbidity and Mortality Weekly Report (MMWR) and should be considered a final draft. It is being posted on AIDSinfo to expedite dissemination of important clinical information. Upon acceptance and publication in MMWR, this draft will be removed and replaced by the published version. In the meantime, readers should be aware that the content of the draft might differ from the content of future published versions. Any corrections/questions concerning this document should be addressed to Ms. Jessica Carrington (e-mail: contactus@aidsinfo.nih.gov).
 
Close window